Ichor Medical Systems said today that its TriGrid electroporation drug-delivery system was tapped for a Phase Ib/II clinical trial to administer an investigational therapeutic HPV DNA vaccine, GX-188E, developed by Genexine Inc.
The trial is designed to test the efficacy of a DNA vaccine combined with an anti-PD-1 therapy in patients with HPV-induced advanced non-resectable cervical cancer.
Ichor’s TriGrid device uses electroporation to boost a cell’s permeability and enable entry of a DNA vaccine. The company said its device has been used in more than 25 clinical studies.
A Phase I trial using the TriGrid system to deliver GX-188E in patients with a precancerous stage of cervical cancer showed promise, according to Ichor – the drug triggered a tumor-specific immune response with “evidence of lesion clearance.”
The Phase Ib/II study, which launched in Korea, is slated to enroll up to 46 patients.
“Ichor’s TriGrid Delivery System is a platform technology used by an increasing number of Ichor partners for clinical delivery of their DNA vaccines where T-cell generation is a critical aspect of the prescribed immunotherapy. We are pleased through our Genexine partnership to expand TriGrid’s use into additional areas of immuno-oncology around the world,” Ichor founder & CEO Robert Bernard said in prepared remarks.
